Equity Overview
Price & Market Data
Price: $2.13
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $723,494,976
Volume: 0
Performance Metrics
1 Week: 13.30%
1 Month: 9.79%
3 Months: -23.10%
6 Months: -9.75%
1 Year: -20.52%
YTD: -19.92%
Company Details
Employees: 220
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.